Details for Patent: 10,004,743
✉ Email this page to a colleague
Which drugs does patent 10,004,743 protect, and when does it expire?
Patent 10,004,743 protects GILOTRIF and is included in one NDA.
Protection for GILOTRIF has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has thirteen patent family members in twelve countries.
Summary for Patent: 10,004,743
| Title: | Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
| Abstract: | The present invention relates to a drying process of BIBW 2992 or the salts thereof, preferably the dimaleate salt, as well as of solid pharmaceutical formulations comprising BIBW2992 or a salt thereof, and to pharmaceutical compositions comprising BIBW 2992 or a salt thereof as the active product ingredient, characterized by a water activity of the formulation of not more than 0.20 or a water content (Karl-Fischer) of not more than 4.2%. |
| Inventor(s): | Albert BARTA |
| Assignee: | Boehringer Ingelheim International GmbH |
| Application Number: | US15/371,252 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,004,743 |
|
Patent Claim Types: see list of patent claims | Composition; Formulation; Dosage form; |
Drugs Protected by US Patent 10,004,743
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | GILOTRIF | afatinib dimaleate | TABLET;ORAL | 201292-001 | Jul 12, 2013 | RX | Yes | No | 10,004,743*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Boehringer Ingelheim | GILOTRIF | afatinib dimaleate | TABLET;ORAL | 201292-002 | Jul 12, 2013 | RX | Yes | No | 10,004,743*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Boehringer Ingelheim | GILOTRIF | afatinib dimaleate | TABLET;ORAL | 201292-003 | Jul 12, 2013 | RX | Yes | Yes | 10,004,743*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,004,743
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Cyprus | 1121782 | ⤷ Start Trial | |||
| Denmark | 2451445 | ⤷ Start Trial | |||
| European Patent Office | 2451445 | ⤷ Start Trial | |||
| Spain | 2731901 | ⤷ Start Trial | |||
| Croatia | P20191005 | ⤷ Start Trial | |||
| Hungary | E044629 | ⤷ Start Trial | |||
| Japan | 2012532180 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
